TY - JOUR AU - B., Dharmaraj AU - G., Prashanth AU - S., Basavaraj PY - 2018/06/22 Y2 - 2024/03/29 TI - The comparisons of the efficacy of two fixed dose combinations, i.e. Salmeterol and Fluticasone vs. Formoterol and Tiotropium bromide in moderate to severe COPD patients JF - International Journal of Basic & Clinical Pharmacology JA - Int J Basic Clin Pharmacol VL - 7 IS - 7 SE - Original Research Articles DO - 10.18203/2319-2003.ijbcp20182681 UR - https://www.ijbcp.com/index.php/ijbcp/article/view/2593 SP - 1351-1356 AB - <p><strong>Background: </strong>Bronchodilators are essential for symptomatic management of all stages of chronic obstructive pulmonary disease (COPD). For patients whose COPD is not sufficiently controlled by monotherapy, combining a ß2-agonist with either inhaled steroid or anticholinergic drug is a convenient way of delivering treatment. Currently, there is no documentation to say that one drug is superior to other or the contrary, but a combination of two drugs is more effective than giving single drug alone in patients suffering from COPD.</p><p><strong>Methods:</strong> The study was prospective, open labelled, randomized, comparative interventional clinical study conducted by the Departments of Pharmacology and Medicine, Basaveshwara Medical College and Hospital, Chitradurga in 60 moderates to severe COPD patients.</p><p><strong>Results:</strong> Both the treatments i.e. Salmeterol/Fluticasone and Tiotropium/Formoterol were equally effective as far as the improvement of the lung functions and Borg dyspnoea score are concerned. The difference in improvement with the combination of Salmeterol/Fluticasone was not statistically significant (p&gt;0.05) compared to the combination of Tiotropium/Formoterol. However, Salmeterol/Fluticasone was found to be better than Tiotropium/Formoterol in improving the lung function of moderate to severe COPD patients.</p><p><strong>Conclusions:</strong> Salmeterol/Fluticasone is efficacious and better than Tiotropium /Formoterol combination for maintenance therapy in moderate to severe COPD patients.</p> ER -